The final mechanism is slowing gastric emptying, inhibiting the inappropriate release of postprandial glucagon, and possibly inhibiting the appetite control center of the brain (Schirra et al., 2006) CLP-1 analogs are currently used for patients with type 2 diabetes (T2DM), as well as for patients with obesity. This evidence concerns the gene GCG and type 2 diabetes mellitus.